| Detected | Trial | Change |
|---|---|---|
| 2026-07-22 | NCT07680946 Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With… |
Recruitment opened |
| 2026-07-21 | NCT06143514 A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk |
date change Primary completion pushed: 2026-06-30 -> 2026-10-31 |
| 2026-07-21 | NCT06143514 A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk |
date change Completion pushed: 2026-06-30 -> 2026-10-31 |
| 2026-07-21 | NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… |
Primary endpoint(s) modified |
| 2026-07-21 | NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… |
Trial sites expanded: 36 -> 39 locations |
| 2026-07-21 | NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… |
date change Primary completion moved earlier: 2027-07-31 -> 2027-05-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05877963 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of… | Relapsing Multiple Sclerosis | Recruiting |
| NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis (RMS) | Active, Not Recruiting |
| NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and… | Relapsing Multiple Sclerosis | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07220252 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of… | Relapsing Multiple Sclerosis | Recruiting |
| Phase 2 | |||
| NCT07673744 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… | Myasthenia Gravis | Recruiting |
| NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… | Multiple Sclerosis | Recruiting |
| NCT07680946 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With… | Schizophrenia | Recruiting |
| Phase 1 | |||
| NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With… | B-cell Mediated Autoimmune Disorders | Recruiting |
| Not specified | |||
| NCT06433765 | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes… | Multiple Sclerosis | Recruiting |
| NCT06143514 | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | Relapsing Multiple Sclerosis | Recruiting |
| NCT06433752 | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI®… | Relapsing Multiple Sclerosis | Recruiting |
| NCT07577583 | Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel | B-cell Mediated Autoimmune Disorders | Not Yet Recruiting |